World Journal of
Pharmacy and Medical Science

ISSN: 3049-3501
Impact Factor: 5.157
CODEN (USA): WJPMAA

Review Article
2026 Volume 2, Issue 9
Page No.: 15-23

# CHRONIC KIDNEY DISEASE: AN OVERVIEW OF PATHOPHYSIOLOGY, DIAGNOSIS, MANAGEMENT AND RECENT ADVANCES

**Vaishnavi Balaji Jadhav*, Dr. Prajakta Kelgaonkar, Shaikh Sadiya Hamid, Maheshvri Kudke**

Department of Pharmacy Practice, Channabasweshwar College of Pharmacy, Latur, Maharashtra, India.

Article Received: 05 July 2026 Article Review: 26 July 2026 Article Accepted: 16 August 2026

***Corresponding Author: Vaishnavi Balaji Jadhav**
Department of Pharmacy Practice, Channabasweshwar College of Pharmacy, Latur, Maharashtra, India.
**DOI:** https://doi.org/10.5281/zenodo.22161566

**How to cite this Article:** Vaishnavi Balaji Jadhav, Dr. Prajakta Kelgaonkar, Shaikh Sadiya Hamid[1], Maheshvri Kudke (2026). CHRONIC KIDNEY DISEASE: AN OVERVIEW OF PATHOPHYSIOLOGY, DIAGNOSIS, MANAGEMENT AND RECENT ADVANCES. World Journal of Pharmacy and Medical Science, 2(9): 15-23.



**ABSTRACT**
Chronic Kidney Disease (CKD) is a long-term disorder characterized by abnormalities of kidney structure or function that persist for at least three months. It is an important cause of morbidity, mortality and healthcare burden worldwide. Diabetes mellitus and hypertension are major causes, while glomerular, hereditary, autoimmune, obstructive, infectious and drug-related conditions may also contribute. Progressive nephron loss reduces the kidney's ability to maintain filtration, fluid and electrolyte balance, acid–base homeostasis and endocrine functions. CKD is frequently silent in its early stages, making timely identification through estimated glomerular filtration rate (eGFR) and urine albumin assessment particularly important. As disease severity increases, patients may develop anemia, cardiovascular disease, hypertension, electrolyte abnormalities, metabolic acidosis, chronic kidney disease–mineral and bone disorder (CKD-MBD), and eventually kidney failure requiring renal replacement therapy. Management aims to identify and treat the underlying cause, slow progression, reduce cardiovascular risk, manage complications and prepare patients for kidney replacement therapy when required. Renin–angiotensin system blockade, sodium–glucose cotransporter-2 (SGLT2) inhibitors, lipid management, dietary measures and appropriate treatment of anemia and CKD-MBD form important components of care. Recent advances, including non-steroidal mineralocorticoid receptor antagonists, newer biomarkers, precision medicine, artificial intelligence and innovations in dialysis and transplantation, are expanding the possibilities for individualized management. This review summarizes the epidemiology, causes, pathophysiology, staging, clinical manifestations, diagnosis, complications, pharmacological and non-pharmacological management, drug interactions, and emerging approaches in CKD.[1–14]

**KEYWORDS**: Chronic kidney disease; eGFR; albuminuria; CKD progression; SGLT2 inhibitors; hypertension; diabetic kidney disease; CKD-MBD; dialysis; kidney transplantation.

## 1. INTRODUCTION

Chronic Kidney Disease (CKD) is a progressive disorder in which structural or functional abnormalities of the kidneys persist over time. The kidneys are essential for removal of metabolic waste, regulation of body water and electrolytes, maintenance of acid–base balance, blood pressure regulation and endocrine functions such as erythropoietin production and activation of vitamin D. Loss of kidney function therefore has consequences that extend well beyond filtration alone.[1–4]

The burden of CKD has increased over recent decades, partly because diabetes, hypertension, obesity and population ageing have become more common. CKD is also associated with substantial cardiovascular risk and can progress to kidney failure. Because early disease often produces few or no symptoms, many patients are diagnosed only after laboratory abnormalities or complications become apparent.[5–7]

CKD should be viewed as a heterogeneous condition rather than a single disease. The cause, degree of albuminuria, rate of decline in kidney function, age, co-morbidities and treatment exposure all influence prognosis. Two patients with the same eGFR may

therefore have different risks depending on their albuminuria and underlying disease.[1,4]

Early detection provides an opportunity to modify risk factors, treat the underlying disease and introduce kidney-protective therapy before substantial nephron loss occurs. Current management therefore emphasizes risk assessment, blood pressure and glycemic control where appropriate, reduction of albuminuria, cardiovascular risk reduction, avoidance of nephrotoxins and regular monitoring.[1,8,9]

This review presents a concise but comprehensive discussion of CKD, with emphasis on clinically relevant diagnosis, staging, complications, pharmacological and non-pharmacological management, drug interactions, and recent developments in therapy.

## 2. Epidemiology and Global Burden

CKD affects a large and growing proportion of the global population. Epidemiological studies have demonstrated substantial variation between regions, reflecting differences in diabetes and hypertension prevalence, environmental exposures, access to healthcare and socioeconomic conditions.[5–7] The worldwide burden is important not only because of kidney failure but also because CKD increases the risk of cardiovascular disease and premature death.

The burden is often underestimated because early CKD is asymptomatic. Patients may have reduced eGFR or albuminuria without noticeable symptoms and may not seek medical attention until disease is advanced. This creates an important role for risk-based screening and opportunistic testing in people with diabetes, hypertension and other recognized risk factors.[1,4]

In low- and middle-income settings, delayed diagnosis may be compounded by limited access to laboratory testing, specialist nephrology care and kidney replacement therapy. Prevention and early intervention are therefore particularly important from a public-health perspective.[7]

| Major contributor | Relevance to CKD | Practical implication |
|---|---|---|
| Diabetes mellitus | Major cause of kidney damage and albuminuria | Optimize glycemic control and use kidney-protective therapy when indicated[8] |
| Hypertension | Causes and accelerates kidney damage | Regular BP assessment and appropriate antihypertensive therapy[9] |
| Obesity/metabolic risk | Associated with diabetes, hypertension and kidney stress | Weight management and lifestyle intervention |
| Glomerular disease | Can produce persistent proteinuria and declining function | Cause-specific evaluation and treatment |
| Hereditary disease | Includes conditions such as polycystic kidney disease | Family history and appropriate genetic/structural assessment |
| Nephrotoxic exposure | Selected medicines and toxins may injure the kidneys | Medication review and avoidance of preventable exposure |

## 3. Etiology and Risk Factors

CKD may result from primary kidney diseases or from systemic disorders that progressively damage renal tissue. Diabetes and hypertension are among the most important causes globally. Other causes include glomerulonephritis, tubulointerstitial disease, hereditary disorders, recurrent obstruction, autoimmune disease, infections and exposure to nephrotoxic substances.[2–7]

### 3.1 Diabetes Mellitus

Diabetic kidney disease develops through a combination of metabolic and hemodynamic mechanisms. Persistent hyperglycemia promotes glomerular injury, oxidative stress and changes in intraglomerular pressure. Albuminuria may develop as kidney damage progresses. Good glycemic control, blood pressure management and use of evidence-based kidney-protective medicines can reduce the risk of progression.[8]

### 3.2 Hypertension

Hypertension may be both a cause and a consequence of CKD. Sustained elevation of systemic pressure increases glomerular stress and vascular injury. As kidney function declines, sodium retention and activation of neurohormonal pathways can further worsen blood pressure. Appropriate blood pressure control is therefore central to slowing CKD progression and reducing cardiovascular events.[9]

### 3.3 Other Causes

Primary glomerular diseases may produce persistent proteinuria, hematuria and declining filtration. Autoimmune diseases can cause inflammatory renal injury, while inherited disorders may produce structural abnormalities and progressive loss of function. Chronic urinary tract obstruction and recurrent infections can also contribute. A careful history, examination, urine assessment and imaging can help direct the diagnostic evaluation.[3,4]

### 3.4 Drug- and Toxin-Related Kidney Injury

Some medicines can cause or worsen kidney injury, particularly in patients who already have reduced renal reserve. Non-steroidal anti-inflammatory drugs (NSAIDs), selected antimicrobial agents, contrast exposure and other nephrotoxic substances may be

relevant depending on the clinical situation. Polypharmacy can also increase the risk of interactions and dosing errors. Regular medication review is therefore an important component of CKD care.[1,3,4]

## 4. Pathophysiology

The central feature of progressive CKD is the gradual loss of functioning nephrons. When nephron number falls, remaining nephrons adapt by increasing their workload. Although this initially helps maintain overall filtration, persistent hyperfiltration can contribute to glomerular injury and further nephron loss. This creates a cycle in which kidney damage promotes compensatory stress, which may in turn accelerate progression.[2–4]

### 4.1 Glomerular Hyperfiltration and Hemodynamic Changes

Loss of functioning nephrons increases the filtration demand on the remaining glomeruli. Altered intraglomerular pressure and vascular tone can promote structural damage and protein leakage. Albuminuria is therefore both a marker of kidney injury and an important indicator of future risk.[1,4]

### 4.2 Inflammation and Fibrosis

Chronic kidney injury can activate inflammatory pathways and promote deposition of extracellular matrix within the renal interstitium. Progressive tubulointerstitial fibrosis reduces the functional renal mass. Once extensive fibrosis has developed, restoration of normal kidney architecture becomes difficult, which explains the progressive nature of established CKD.[2,3]

### 4.3 Neurohormonal Activation

Activation of the renin–angiotensin–aldosterone system contributes to hypertension, intraglomerular pressure and proteinuria. This pathway provides an important therapeutic target because renin–angiotensin system inhibitors can reduce albuminuria and help protect kidney function in appropriate patients.[1,9]

### 4.4 Metabolic and Endocrine Consequences

As filtration declines, the kidney becomes less able to excrete acid, potassium and other metabolic products and less able to maintain mineral balance. Reduced erythropoietin production contributes to anemia, while disturbed vitamin D metabolism and phosphate handling contribute to CKD-MBD. These changes explain many of the systemic manifestations seen in advanced disease.[3,4]

## 5. Classification and Staging of CKD

CKD is commonly categorized using both eGFR and albuminuria. eGFR reflects the level of kidney filtration, while albuminuria provides information about kidney damage and prognosis. The combination of these measures gives a more informative picture of risk than either measure alone.[1,4]

| G category | eGFR (mL/min/1.73 m²) | General description |
|---|---|---|
| G1 | ≥90 | Normal or high; CKD requires another marker of kidney damage |
| G2 | 60–89 | Mildly decreased; CKD requires another marker of kidney damage |
| G3a | 45–59 | Mild to moderately decreased |
| G3b | 30–44 | Moderately to severely decreased |
| G4 | 15–29 | Severely decreased |
| G5 | <15 | Kidney failure |

Albuminuria is commonly categorized as A1, A2 or A3 according to urine albumin-to-creatinine ratio. Higher albuminuria generally indicates greater kidney and cardiovascular risk. Combining G and A categories supports risk stratification and helps determine the intensity of monitoring and management.[1]

| Albuminuria category | ACR | Interpretation |
|---|---|---|
| A1 | <30 mg/g | Normal to mildly increased |
| A2 | 30–300 mg/g | Moderately increased |
| A3 | >300 mg/g | Severely increased |

## 6. Clinical Manifestations

Clinical presentation varies with the cause and stage of CKD. Early disease may be clinically silent and identified only through eGFR, urine albumin or other laboratory abnormalities. As kidney function declines, systemic symptoms become more likely.[3,4]

Common manifestations include fatigue, weakness, reduced appetite, nausea, vomiting, nocturia, edema and hypertension. Advanced disease may produce pruritus, muscle cramps, sleep disturbance, cognitive difficulty, shortness of breath and weight loss. Uremic symptoms may occur in severe kidney failure.[3]

The clinical picture may also reflect complications rather than kidney dysfunction itself. For example, fatigue may be related to anemia, dyspnea may be associated with fluid overload, and bone pain may occur in the setting of CKD-MBD. A structured assessment helps identify these contributing factors.

## 7. Diagnosis and Evaluation

Diagnosis requires evidence of kidney damage or reduced kidney function that persists for at least three months. A single abnormal creatinine or urine result is

not sufficient to establish chronicity unless previous information supports the diagnosis.[1,4]

### 7.1 Estimated Glomerular Filtration Rate

Serum creatinine is used with validated equations to estimate GFR. eGFR provides an accessible measure of kidney function and is central to staging, medication assessment and risk stratification. Creatinine-based estimates may be influenced by muscle mass and other patient characteristics, so results should be interpreted in clinical context.[1,4]

### 7.2 Albuminuria Assessment

Urine albumin-to-creatinine ratio (ACR) is an important test for detecting albuminuria. Persistent albuminuria may indicate glomerular damage even when eGFR is relatively preserved. It is also useful for assessing progression risk and response to kidney-protective treatment.[1,4]

### 7.3 Additional Investigations

Urinalysis may identify hematuria, proteinuria or other abnormalities. Blood tests can assess hemoglobin, electrolytes, bicarbonate, calcium and phosphorus. Ultrasound can provide information about kidney size, obstruction and structural abnormalities. When the cause remains uncertain, selected patients may require additional serological tests or kidney biopsy.[3,4]

| Investigation | Main purpose |
|---|---|
| Serum creatinine/eGFR | Assess kidney filtration |
| Urine ACR | Detect and quantify albuminuria |
| Urinalysis | Identify blood, protein and other abnormalities |
| Electrolytes/bicarbonate | Assess metabolic and electrolyte complications |
| Hemoglobin | Screen for anemia |
| Calcium/phosphorus | Assess mineral and bone abnormalities |
| Renal ultrasound | Evaluate structure and obstruction |
| Kidney biopsy | Selected cases requiring tissue diagnosis |

## 8. Complications of CKD

CKD affects multiple organ systems because the kidneys contribute to homeostasis and endocrine regulation. Complications become more frequent as kidney function declines and may themselves increase morbidity and mortality.[3,4]

### 8.1 Cardiovascular Disease

Cardiovascular disease is a major cause of morbidity and mortality in CKD. Hypertension, albuminuria, vascular disease, anemia, inflammation and disturbances in mineral metabolism contribute to cardiovascular risk. Cardiovascular risk reduction should therefore be integrated into kidney care rather than treated as a separate problem.[5,9]

### 8.2 Anemia

Anemia in CKD is multifactorial, with reduced erythropoietin production being an important contributor. Iron deficiency, inflammation and shortened red-cell survival may also contribute. Symptoms can include fatigue, reduced exercise tolerance and breathlessness. Evaluation should identify reversible causes before considering erythropoiesis-stimulating therapy.[3,4]

### 8.3 CKD-Mineral and Bone Disorder

Declining kidney function disrupts phosphate excretion, vitamin D metabolism and parathyroid regulation. The resulting abnormalities can contribute to secondary hyperparathyroidism, altered bone turnover and vascular calcification. Management requires attention to calcium, phosphorus, parathyroid hormone and vitamin D status rather than treating a single laboratory value in isolation.[3,4]

### 8.4 Hyperkalemia and Metabolic Acidosis

Reduced renal potassium excretion can lead to hyperkalemia, particularly in advanced CKD or when medicines affecting the renin–angiotensin–aldosterone system are used. Reduced acid excretion can also produce metabolic acidosis. Both conditions require monitoring and individualized treatment.[1,3]

### 8.5 Fluid Overload and Hypertension

Sodium and water retention can produce edema, weight gain, pulmonary congestion and worsening blood pressure. Diuretics may help manage volume overload when clinically appropriate, while dietary sodium reduction can support blood pressure and fluid management.[9,10]

### 8.6 Kidney Failure

Advanced CKD may progress to kidney failure, at which point patients may require hemodialysis, peritoneal dialysis or kidney transplantation. Preparation should begin before urgent need arises so that patients can receive education and appropriate access planning.[3,4]

## 9. Management of CKD

Management is individualized according to cause, CKD stage, albuminuria, cardiovascular risk, complications and patient preferences. The main objectives are to slow progression, reduce cardiovascular events, manage symptoms and complications, and prepare for kidney replacement therapy when necessary.[1,8–10]

### 9.1 Lifestyle and Dietary Measures

Lifestyle intervention forms the foundation of CKD care. Sodium intake should generally be reduced, while

protein intake should be individualized according to kidney function, nutritional status and professional dietary advice. Potassium and phosphorus restrictions are not automatically required for every patient and should be guided by laboratory results and disease stage.[10]

Regular physical activity, healthy weight management, smoking cessation and adequate sleep support cardiovascular health. Fluid intake should be individualized rather than universally increased or restricted, because the appropriate amount depends on kidney function, urine output, edema and other clinical factors.

| Measure | Purpose |
|---|---|
| Sodium reduction | Supports BP and volume control[9,10] |
| Individualized protein intake | Supports nutritional health while avoiding unnecessary excess[10] |
| Physical activity | Improves cardiovascular and functional health |
| Weight management | Reduces metabolic and cardiovascular risk |
| Smoking cessation | Reduces cardiovascular and renal risk |
| Avoid unnecessary nephrotoxins | Reduces preventable kidney injury |
| Regular follow-up | Allows early recognition of progression and complications |

### 9.2 Blood Pressure Management

Blood pressure control is a central strategy for slowing CKD progression and reducing cardiovascular risk. ACE inhibitors or angiotensin receptor blockers are particularly important in patients with albuminuria because they reduce intraglomerular pressure and protein loss in addition to lowering systemic blood pressure.[1,9]

Renal function and potassium should be monitored after initiation or dose changes of renin–angiotensin system blockers. A medication should not be stopped solely because of a small expected change in creatinine without clinical assessment; instead, volume status, concurrent medicines and the magnitude of change should be reviewed.

### 9.3 Glycemic Management and Kidney Protection

For patients with diabetes and CKD, glycemic management should be individualized. SGLT2 inhibitors have become an important component of kidney-protective therapy because clinical trials have demonstrated reductions in progression of kidney disease and cardiovascular outcomes in appropriate patients.[8,11,12]

### 9.4 SGLT2 Inhibitors

Dapagliflozin and empagliflozin have demonstrated kidney and cardiovascular benefits in CKD populations. Their effects are not limited to glucose lowering and extend to patients without diabetes in appropriate clinical settings [11,12]. These medicines may cause an early hemodynamic change in eGFR, so clinicians should interpret renal function trends in context and monitor for volume depletion or other adverse effects.

### 9.5 Non-steroidal Mineralocorticoid Receptor Antagonists

Finerenone is a non-steroidal mineralocorticoid receptor antagonist studied in patients with CKD associated with type 2 diabetes. Clinical evidence indicates cardiovascular and kidney benefits, although potassium monitoring is necessary because mineralocorticoid receptor blockade can increase hyperkalemia risk.[13]

### 9.6 Lipid Management

Dyslipidemia contributes to cardiovascular risk in CKD. Statin therapy may therefore be appropriate according to age, cardiovascular risk and CKD stage. Lipid management should be considered as part of comprehensive cardiovascular risk reduction rather than solely as a measure of kidney function.

### 9.7 Management of Anemia

Anemia management begins with assessment of hemoglobin and evaluation for iron deficiency and other reversible causes. Iron therapy may be used when indicated. Erythropoiesis-stimulating agents are considered in selected patients according to hemoglobin level, symptoms, iron status and treatment goals. Therapy should be individualized because excessive correction of anemia may carry cardiovascular risks.[1,3]

### 9.8 CKD-MBD Management

Management of CKD-MBD involves dietary measures and correction of relevant biochemical abnormalities. Phosphate binders, vitamin D-related therapies and calcimimetics may be used in selected patients. Treatment should be based on persistent abnormalities and the overall clinical context rather than on an isolated laboratory result.[3,4]

### 9.9 Hyperkalemia and Metabolic Acidosis

Hyperkalemia requires assessment of contributing medicines, diet, kidney function and acute illness. Potassium-binding agents may be considered in appropriate patients. Metabolic acidosis may be managed with oral bicarbonate in selected patients after considering volume status and other factors.

### 9.10 Diuretics and Fluid Management

Loop diuretics such as furosemide are useful for patients with clinically significant fluid overload. Their role is primarily symptom and volume management rather than direct reversal of CKD. Dosing should be individualized according to kidney function, urine output and response.

**10. Drug–Drug Interactions and Medication Safety**

CKD increases the risk of medication-related problems because reduced kidney function can alter drug clearance and because patients often have several co-morbidities requiring multiple medicines. Dose adjustment according to kidney function and regular medication reconciliation are therefore essential.[1,3,4]

| Combination/problem | Potential concern | Management principle |
|---|---|---|
| ACE inhibitor/ARB + potassium-raising therapy | Hyperkalemia | Monitor potassium and renal function[9] |
| ACE inhibitor/ARB + NSAID | Reduced renal perfusion and AKI risk | Avoid unnecessary NSAID use |
| SGLT2 inhibitor + intensive diuresis | Volume depletion/hypotension | Assess hydration and diuretic requirement[11,12] |
| Phosphate binders + oral medicines | Reduced absorption of co-administered drugs | Separate administration when appropriate |
| Renally cleared medicines in low eGFR | Drug accumulation | Check renal dosing and monitoring |
| Multiple nephrotoxic agents | Additive kidney injury | Review necessity and alternatives |

Drug interactions are not limited to pharmacokinetic changes. Additive effects can also be clinically important. For example, several medicines may independently increase potassium, lower blood pressure or contribute to dehydration. The pharmacist and prescribing team should therefore consider the total medication burden rather than evaluating each medicine in isolation.

**11. Renal Replacement Therapy**

When CKD progresses to kidney failure, renal replacement therapy may become necessary. The main options are hemodialysis, peritoneal dialysis and kidney transplantation. The choice depends on medical suitability, patient preference, availability, social circumstances and local resources.[3,4]

**11.1 Hemodialysis**

Hemodialysis removes metabolic waste and excess fluid through an extracorporeal circuit. Treatment is usually performed on a regular schedule. Vascular access planning is important because a mature access can improve long-term dialysis delivery.

**11.2 Peritoneal Dialysis**

Peritoneal dialysis uses the peritoneal membrane as a semipermeable surface for exchange of solutes and fluid. It may offer greater flexibility for some patients and can be performed outside a conventional dialysis center, although infection and other complications require careful monitoring.

**11.3 Kidney Transplantation**

Kidney transplantation can provide a more complete replacement of renal function than dialysis for suitable patients. It requires evaluation of the recipient and donor, long-term immunosuppression and monitoring for rejection and infection. Early referral allows appropriate assessment and preparation.

**12. Role of the Clinical Pharmacist in CKD Management**

Clinical pharmacists can contribute substantially to safe and effective CKD care. Their role is especially relevant because CKD commonly involves polypharmacy, renal dose adjustments and medicines with clinically important interactions.

**12.1 Medication Reconciliation**

A pharmacist can review prescription medicines, over-the-counter products and herbal preparations, identify duplication and determine whether any medicine may be worsening kidney function or causing preventable adverse effects.

**12.2 Renal Dose Adjustment**

Many medicines require dose or interval modification as eGFR declines. Pharmacists can identify medicines that require adjustment and communicate recommendations to prescribers. This reduces the risk of accumulation and toxicity while maintaining therapeutic effectiveness.

**12.3 Interaction Monitoring**

Pharmacists can screen for drug–drug and drug–disease interactions, particularly those involving potassium, blood pressure, renal perfusion and nephrotoxicity. They can also help patients understand administration schedules when medicines such as phosphate binders interfere with absorption of other drugs.

**12.4 Adherence and Patient Education**

CKD treatment often involves several long-term medicines. Clear counselling about purpose, dosing, adverse effects and monitoring can improve adherence. Education should also cover avoidance of self-medication with NSAIDs and the importance of reporting dehydration, reduced urine output or other warning symptoms.

**12.5 Pharmacovigilance**

Documentation and reporting of suspected adverse drug reactions can improve medication safety. Pharmacists

can also help track changes in kidney function and identify patterns suggesting drug-related harm.

## 13. Recent Advances in CKD Management

The management of CKD has changed substantially with the introduction of kidney-protective therapies and improved approaches to risk assessment. SGLT2 inhibitors have demonstrated benefits beyond glucose lowering, while finerenone has provided an additional option for selected patients with diabetic CKD.[11–13]

### 13.1 New Biomarkers

Creatinine remains the most widely used marker of kidney filtration, but additional biomarkers are being studied to improve early detection and risk prediction. Cystatin C may provide complementary information about filtration in selected patients. Other biomarkers, including kidney injury molecule-1 (KIM-1), are being investigated for their potential to identify renal injury earlier, although their routine clinical role is not yet equivalent to established measures.[1,14]

### 13.2 Precision Medicine

Precision medicine aims to integrate clinical, biochemical, genetic and molecular information to tailor prevention and treatment. In CKD, future approaches may help distinguish patients who are more likely to progress rapidly or respond differently to particular therapies. At present, implementation remains limited by the complexity of CKD and the need for validated predictive markers.

### 13.3 Artificial Intelligence

Artificial intelligence and machine-learning methods can analyze large clinical datasets and may assist with risk prediction, identification of rapid kidney function decline and clinical decision support. Their potential is promising, but models require external validation and careful assessment of bias, interpretability and data quality before they are routinely relied upon.

### 13.4 Advances in Dialysis and Transplantation

Research is also focused on improving dialysis efficiency, patient experience and home-based treatment, as well as improving transplant outcomes. Innovations in monitoring, access management and immunosuppressive strategies may further support personalized care.

| Recent approach | Potential benefit | Current consideration |
|---|---|---|
| SGLT2 inhibitors | Reduce kidney and cardiovascular risk[11,12] | Patient selection and monitoring |
| Finerenone | Kidney and cardiovascular benefit in selected diabetic CKD[13] | Hyperkalemia monitoring |
| Cystatin C and other biomarkers | Potentially improved risk assessment | Additional validation and clinical integration[14] |
| Precision medicine | Individualized risk and treatment selection | Evidence and implementation remain developing |
| AI/ML | Risk prediction and decision support | Validation, bias and interpretability |
| Dialysis innovation | Improved flexibility and treatment delivery | Access and resource requirements |

## 14. Patient-Centered Care and Quality of Life

CKD management should address more than laboratory targets. Fatigue, itching, sleep disturbance, dietary restrictions, medication burden and uncertainty about disease progression can affect quality of life. In advanced disease, decisions about dialysis or transplantation also have major personal and social consequences.

Patient education should therefore be continuous rather than limited to the time of diagnosis. Patients should understand the purpose of monitoring, the importance of medication adherence and the symptoms that require prompt medical attention. Shared decision-making can help align treatment with patient preferences and practical circumstances.

Family involvement may be useful when patients require assistance with diet, medicines or dialysis planning. Clear communication between primary care, nephrology, pharmacy, dietetics and other professionals can reduce fragmentation of care.

## 15. Prevention and Early Detection

Because CKD may remain silent for years, prevention and early detection are essential. Individuals with diabetes, hypertension, cardiovascular disease or a strong family history of kidney disease may benefit from periodic assessment according to clinical risk. Early identification of albuminuria or reduced eGFR creates an opportunity for intervention before advanced complications develop.[1,4,7]

Population-level prevention also depends on controlling diabetes and hypertension, reducing obesity-related risk, promoting healthy dietary patterns and improving awareness of kidney disease. Avoidance of unnecessary nephrotoxic exposure and safe prescribing are additional practical measures.

A useful prevention strategy is to combine risk-factor modification with regular monitoring rather than waiting for symptoms. This is particularly important because

symptoms often appear only after substantial loss of kidney function.

**16. Future Perspectives**

Future CKD management is likely to become increasingly risk-based and individualized. Combining eGFR, albuminuria, clinical characteristics and emerging biomarkers may improve prediction of progression. Molecular profiling and precision medicine may eventually help identify distinct biological subtypes of CKD that respond differently to treatment.

Digital health and artificial intelligence may support remote monitoring and earlier recognition of deterioration. At the same time, new drug classes and combinations may provide additional kidney protection. Continued research is needed to determine which emerging tools provide meaningful improvement in outcomes rather than simply adding complexity.

Equity should remain an important consideration. Effective innovations must be accessible, affordable and practical in different healthcare settings. The long-term goal is not only to delay kidney failure but also to improve cardiovascular outcomes, preserve functional status and maintain quality of life.

**17. Limitations and Challenges**

CKD is heterogeneous, and progression is not identical in all patients. The underlying cause, degree of albuminuria, co-morbid disease and treatment response all influence outcomes. In addition, some symptoms and laboratory abnormalities may have several possible causes, making attribution difficult.

Polypharmacy and fragmented care can lead to medication-related problems. Patients may also have difficulty following complex dietary and medication recommendations. Access to specialist care, dialysis and transplantation varies widely between regions. These factors highlight the need for practical, multidisciplinary and patient-centered approaches.

Although recent therapies have improved outcomes, not every patient is eligible for every treatment. Monitoring requirements, adverse effects, cost and availability can influence implementation. Continued research should therefore focus on real-world effectiveness as well as clinical trial efficacy.

**18. CONCLUSION**

Chronic Kidney Disease is a major long-term health problem with effects that extend from impaired filtration to cardiovascular, hematological, metabolic and skeletal complications. Diabetes and hypertension remain major contributors, while a wide range of other renal and systemic diseases can produce progressive kidney damage [2–7].

Because early CKD is often asymptomatic, diagnosis based on persistent reduction in eGFR and/or markers of kidney damage such as albuminuria is essential. Appropriate staging helps determine prognosis and guides the intensity of monitoring and treatment.[1,4]

Management requires a combination of lifestyle measures, control of blood pressure and diabetes when present, kidney-protective pharmacotherapy, cardiovascular risk reduction, management of anemia and CKD-MBD, medication safety and preparation for kidney replacement therapy when necessary. SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists have expanded the therapeutic options available for selected patients.[8,11–13]

Recent developments in biomarkers, precision medicine, artificial intelligence, dialysis and transplantation offer further possibilities for individualized care. However, these advances should complement rather than replace the fundamentals of early detection, evidence-based treatment, medication review, patient education and multidisciplinary follow-up. A coordinated approach involving physicians, pharmacists, nurses, dietitians and patients remains central to improving long-term outcomes in CKD.

**REFERENCES**


1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 2024; 105(Suppl 4): S1–S150.
2. Levey AS, Coresh J. Chronic kidney disease. Lancet, 2012; 379(9811): 165–180.
3. Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet, 2017; 389(10075): 1238–1252.
4. Chen TK, Knicely DH, Grams ME. Chronic Kidney Disease Diagnosis and Management: A Review. JAMA, 2019; 322(13): 1294–1304.
5. Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet, 2021; 398(10302): 786–802.
6. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017. Lancet, 2020; 395(10225): 709–733.
7. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: Global dimension and perspectives. Lancet, 2013; 382(9888): 260–272.
8. KDIGO. 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int., 2022; 102(Suppl): S1–S127.
9. KDIGO. 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int, 2021; 99(Suppl): S1–S87.
10. National Kidney Foundation. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis, 2020; 76(3 Suppl 1): S1–S107.

11. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 2020; 383: 1436–1446.
12. Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med, 2023; 388: 117–127.
13. Agarwal R, Filippatos G, Pitt B, et al. Cardiovascular and Kidney Outcomes with Finerenone in Chronic Kidney Disease. N Engl J Med, 2021; 385: 2252–2263.
14. Levin A, Stevens PE. Summary of KDIGO CKD Guideline. Kidney Int, 2024; 105(Suppl 4): S1–S10.
15. Taal MW, Chertow GM, Marsden PA, et al. Brenner and Rector's The Kidney. 12th ed. Elsevier, 2024.
16. Jameson JL, Fauci AS, Kasper DL, et al. Harrison's Principles of Internal Medicine. 22nd ed. McGraw-Hill; 2024.
17. National Institute of Diabetes and Digestive and Kidney Diseases. Chronic Kidney Disease (CKD). Bethesda, MD: NIDDK, 2024.
18. Centers for Disease Control and Prevention. Chronic Kidney Disease Initiative. Atlanta: CDC, 2024.
19. World Health Organization. Noncommunicable Diseases: Chronic Kidney Disease. Geneva: WHO, 2023.
20. Kidney Disease: Improving Global Outcomes (KDIGO). KDIGO Clinical Practice Guidelines. Kidney Int Suppl., 2024.